Latest News

Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.

Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.

Final 96-week phase 1b data show sustained UPCR reduction and stable eGFR about 1.5 years after the last mezagitamab dose, with no serious adverse events.

Final VISIONARY data show sibeprenlimab held eGFR steady over 24 months, with a 4.5 mL/min/1.73 m² per year slope advantage and fewer kidney outcome events vs placebo.

Jonathan Barratt, PhD, FRCP, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack final ORIGIN 3 eGFR data for atacicept in IgAN.

In phase 3 INTREPID, lutikizumab beat placebo on HiSCR75 at week 16 and met all 8 ranked secondary end points in moderate to severe HS.

For Eczema Awareness Month, Keira Barr, MD, explains the stress-itch cycle in atopic dermatitis and questions to uncover its hidden burden in clinic.

The 150 mg once-daily pellet formulation gives patients aged ≥ 12 years a capsule alternative for HAE prophylaxis.

A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.

A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.

Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.

A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.

Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.

At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.

FDA approves bepirovirsen after phase 3 trials show 19% achieved functional cure at 24 weeks off all hepatitis B treatment.

Preview 8 late-breaking studies and HCPLive's investigator interviews at ASN Kidney Week 2026, spanning IgAN, dialysis, transplantation, and CKD.

Todd Schlesinger, MD, discusses Ameluz PDT for sBCC, adjuvant cemiplimab, remibrutinib for symptomatic dermographism, and nonsurgical skin cancer care.

In an interim extension analysis presented at NACFC 2026, 37.5% of young children with CF in a PERT substudy stopped enzyme therapy on the regimen.

Day 2 highlights from Phoenix covering PE intervention trials, pulmonary hypertension diagnostics, ILD telomere biology, and more.

In 503 patients with ILD, telomere length below the 10th percentile was linked to UIP pattern on CT and higher MIL-UIP scores but not greater fibrosis extent.

Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.

Clinicians described how steroid exposure from multiple prescribers shapes biologic decisions in asthma and COPD.

From oral IL-23 blockade in UC to sex-specific FIT thresholds and a swallowable Barrett’s test, these are 7 trials from ACG 2026 clinicians should know.